Schloendorff v. New York Hospital, 211 N.Y. 125, 129 (1914).
2.
CompareN. W.Dickertet al., “Reframing Consent for Clinical Research: A Function-Based Approach, American Journal of Bioethics17, no. 12 (2017): 3-11, with T. L. Beauchamp, “The Idea of a ‘Standard View’ of Informed Consent,” American Journal of Bioethics 17, no. 12 (2017): 1-2.
3.
See, e.g., G. J.Annas, “Informed Consent: Charade or Choice?,”Journal of Law, Medicine & Ethics45, no. 1 (2017): 10-11; L. M. Beskow, L. Lin, C. B. Dombeck, E. Gao, and K. P. Weinfurt, “Improving Biobank Consent Comprehension: A National Randomized Survey to Assess the Effect of a Simplified Form and Review/Retest Intervention,” Genetics in Medicine 19, no. 5 (2017): 505-512.
See, e.g., C.Grady, S. R.Cummings, M. C.Rowbotham, M. V.McConnell, E. A.Ashley, and G.Kang, “Informed Consent,”New England Journal of Medicine376, no. 9 (2017): 856-867; E. E. Anderson, S. B. Newman, and A. K. Matthews, “Improving Informed Consent: Stakeholder Views,” AJOB Empirical Bioethics 8, no. 3 (2017): 178-188.
6.
See, e.g., S.Kalkman, S. Y. H.Kim, G. J. M. W.van Thiel, D. E.Grobbee, and J. J. M.Delden, “Ethics of Informed Consent for Pragmatic Trials with New Interventions,”Value in Health20, no. 7 (2017): 902-908.
7.
See, e.g., G. E.Hendersonet al., “The Challenge of Informed Consent and Return of Results in Translational Genomics: Empirical Analysis and Recommendations,”Journal of Law, Medicine & Ethics42, no. 3 (2014): 344-355.
8.
National Institutes of Health, All of Us Research Program, available at <https://allofus.nih.gov/> (last visited January 10, 2018).
Schloendorff v. New York Hospital, 211 N.Y. 125 (1914).
12.
P. A.Lombardo, “Phantom Tumors and Hysterical Women: Revising our View of the Schloendorff Case,”Journal of Law, Medicine & Ethics33, no. 4 (2005): 791-801.
13.
J.Katz, The Silent World of Doctor and Patient (New York: Free Press, 1984).
14.
Salgo v. Leland Stanford Jr. University Board of Trustees, 154 Cal.App.2d 560.
15.
A. M.Capron, “Where Did Informed Consent for Research Come From?”Journal of Law, Medicine & Ethics46, no. 1 (2018): 12-29.
16.
S.Gehlert and J.Mozersky, “Seeing Beyond the Margins: Challenges to Informed Inclusion of Vulnerable Populations in Research,”Journal of Law, Medicine & Ethics46, no. 1 (2018): 30-43.
17.
J. N.Henderson, “Personal Experiences with Tribal IRBs, Hidden Hegemony of Researchers, and the Need for an Inter-cultural Approach: Views from an American Indian Researcher,”Journal of Law, Medicine & Ethics46, no. 1 (2018): 44-51.
18.
M.Lamkin and C.Elliott, “Avoiding Exploitation in Phase I Clinical Trials: More than (Un)Just Compensation,”Journal of Law, Medicine & Ethics46, no. 1 (2018): 52-63.
19.
A. S.Porter and E.Kodish, “The Ethics of Using Complementary Medicine in Pediatric Oncology Trials: Reconciling Challenges,”Journal of Law, Medicine & Ethics46, no. 1 (2018): 64-71.
20.
M. H.Biros, “Capacity, Vulnerability, and Informed Consent for Research,”Journal of Law, Medicine & Ethics46, no. 1 (2018): 72-78.
21.
W.Burke, L. M.Beskow, S. B.Trinidad, S. M.Fullerton, and K.Brelsford, “Informed Consent in Translational Genomics: Insufficient Without Trustworthy Governance,”Journal of Law, Medicine & Ethics46, no. 1 (2018): 79-86.
22.
S. M.Wolf, E.Scholtes, B. A.Koenig, G. M.Petersen, S. A.Berry, L. M.Beskow, M. B.Daly, C. V.Fernandez, R. C.Green, B. S.LeRoy, N. M.Lindor, P. P.O'Rourke, C. R.Breitkopf, M. A.Rothstein, B.Van Ness, and B. S.Wilfond, “Pragmatic Tools for Sharing Genomic Research Results with the Relatives of Living and Deceased Research Participants,”Journal of Law, Medicine & Ethics46, no. 1 (2018): 87-109.
23.
J.Wilbanks, “Design Issues in E-Consent,”Journal of Law, Medicine & Ethics46, no. 1 (2018): 110-118.
24.
E.Vayena and A.Blasimme, “Health Research with Big Data: Time for Systemic Oversight,”Journal of Law, Medicine & Ethics46, no. 1 (2018): 119-129.